CD274 and neoplasm: The range of LC responses to immunotherapies remains variable, depending mostly on the mutational burden of the tumor and the subsequent neoantigen diversity which, together with a range of other factors (such as programmed death-ligand 1 [PD-L1] expression, interferon-γ [IFN-γ] signaling, and others) determine T cell reactivity against them (Schumacher and Schreiber, 2015; Hendriks et al., 2018; Hegde and Chen, 2020).